The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined by a BMI ≥30 kg/m2 who are on dolutegravir-based ART. Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0 mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of participants who screen and enroll among those approached
Timeframe: Measured at screening
Time to reach study enrollment target
Timeframe: Measured at enrollment
Study retention rate at 12 weeks
Timeframe: Measured at Visit 4 at 12 weeks
Study retention rate at 24 weeks
Timeframe: Measured at End of Study at 24 weeks
Rate of adherence to treatment over 12 weeks
Timeframe: Measured at Visit 4 at 12 weeks
Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management
Timeframe: Measured at End of Study at 24 weeks